Finance

Beta
Lists
CCCC:NASDAQ
C4 Therapeutics, Inc
$3.85
-7.67%
(-0.32) 1D
$3.81
-1.04% (-0.040)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CCCC...
Open
$4.15
High
$4.16
Low
$3.78
Mkt. cap
425.68M
Avg. vol.
2.81M
Volume
2.13M
52-wk high
$4.60
52-wk low
$1.36
EPS
-$1.18
Beta
2.92
Shares outstanding
110.57M
No. of employees
104
Open
$4.15
High
$4.16
Low
$3.78
Mkt. cap
425.68M
Avg. vol.
2.81M
Volume
2.13M
52-wk high
$4.60
52-wk low
$1.36
EPS
-$1.18
Beta
2.92
Shares outstanding
110.57M
No. of employees
104
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to CCCC in the past 3 months
Strong Buy
Buy
4
Hold
0
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CCCC in the last 3 months.
Highest
Current $3.85
$14.00 (+263.64%)
Average
$10.33 (+168.31%)
Lowest
$7.00 (+81.82%)
News stories
From sources across the web
About C4 Therapeutics, Inc
CEO-
Employees104
Founded2015
HeadquartersWatertown, Massachusetts, United States
SectorBiotechnology
Websitec4therapeutics.com
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.20 / -$0.26
+23.08%beat
Revenue / Est. (USD)
6.15M / 4.42M
+39.29%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.46M
11.23M
11.02M
6.15M
Cost of goods sold
26.20M
25.99M
-70.28M
-
Cost of revenue
26.20M
25.99M
-70.28M
-
Research and development expenses
-
-
95.26M
24.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.77M
8.92M
9.18M
9.33M
Operating expense
8.77M
8.92M
104.44M
33.94M
Total operating expenses
34.96M
34.91M
34.16M
33.94M
Operating income
-28.50M
-23.68M
-23.14M
-27.78M
Other non operating income
-
-
-
-
EBT including unusual items
-26.02M
-32.17M
-20.36M
-25.13M
EBT excluding unusual items
-27.38M
-21.43M
-21.23M
-25.13M
Income tax expense
-
-
121.00K
-
Effective tax rate
-
-
-0.59%
-
Other operating expenses
-
-
-
-
Net income
-26.02M
-32.17M
-20.49M
-25.13M
Net profit margin
-402.60%
-286.43%
-185.97%
-408.47%
Earnings per share
-0.37
-0.30
-0.18
-0.20
Interest and investment income
1.12M
2.25M
1.92M
2.66M
Interest expense
-
-
-
-
Net interest expenses
1.12M
2.25M
1.92M
2.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.89M
-23.22M
-22.72M
-27.38M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer